BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 36613714)

  • 1. RAGE Inhibitors for Targeted Therapy of Cancer: A Comprehensive Review.
    Faruqui T; Khan MS; Akhter Y; Khan S; Rafi Z; Saeed M; Han I; Choi EH; Yadav DK
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycation reaction and the role of the receptor for advanced glycation end-products in immunity and social behavior.
    Leerach N; Harashima A; Munesue S; Kimura K; Oshima Y; Goto H; Yamamoto H; Higashida H; Yamamoto Y
    Glycoconj J; 2021 Jun; 38(3):303-310. PubMed ID: 33108607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAGE and its ligands: from pathogenesis to therapeutics.
    Jangde N; Ray R; Rai V
    Crit Rev Biochem Mol Biol; 2020 Dec; 55(6):555-575. PubMed ID: 32933340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AGEs, RAGEs and s-RAGE; friend or foe for cancer.
    Ahmad S; Khan H; Siddiqui Z; Khan MY; Rehman S; Shahab U; Godovikova T; Silnikov V; Moinuddin
    Semin Cancer Biol; 2018 Apr; 49():44-55. PubMed ID: 28712719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Characteristics of RAGE and Advances in Small-Molecule Inhibitors.
    Kim HJ; Jeong MS; Jang SB
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34199060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting RAGE Signaling in Inflammatory Disease.
    Hudson BI; Lippman ME
    Annu Rev Med; 2018 Jan; 69():349-364. PubMed ID: 29106804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor for Advanced Glycation End Products (RAGE): A Pivotal Hub in Immune Diseases.
    Yue Q; Song Y; Liu Z; Zhang L; Yang L; Li J
    Molecules; 2022 Aug; 27(15):. PubMed ID: 35956875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors.
    Singh H; Agrawal DK
    Drug Dev Res; 2022 Sep; 83(6):1257-1269. PubMed ID: 35781678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.
    Leung SS; Forbes JM; Borg DJ
    Curr Diab Rep; 2016 Oct; 16(10):100. PubMed ID: 27612847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The biology of the receptor for advanced glycation end products and its ligands.
    Schmidt AM; Yan SD; Yan SF; Stern DM
    Biochim Biophys Acta; 2000 Dec; 1498(2-3):99-111. PubMed ID: 11108954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings.
    Stern D; Yan SD; Yan SF; Schmidt AM
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1615-25. PubMed ID: 12453678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Potential of Receptor for Advanced Glycation End Products (RAGE) as a Therapeutic Target for Lung Associated Diseases.
    Khaket TP; Kang SC; Mukherjee TK
    Curr Drug Targets; 2019; 20(6):679-689. PubMed ID: 30457049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The receptor for advanced glycation end products and acute lung injury/acute respiratory distress syndrome.
    Guo WA; Knight PR; Raghavendran K
    Intensive Care Med; 2012 Oct; 38(10):1588-98. PubMed ID: 22777515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All the "RAGE" in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses.
    Oczypok EA; Perkins TN; Oury TD
    Paediatr Respir Rev; 2017 Jun; 23():40-49. PubMed ID: 28416135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAGE: a multi-ligand receptor unveiling novel insights in health and disease.
    Alexiou P; Chatzopoulou M; Pegklidou K; Demopoulos VJ
    Curr Med Chem; 2010; 17(21):2232-52. PubMed ID: 20459381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.
    Schmidt AM; Yan SD; Wautier JL; Stern D
    Circ Res; 1999 Mar; 84(5):489-97. PubMed ID: 10082470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer-a Review.
    Palanissami G; Paul SFD
    Horm Cancer; 2018 Oct; 9(5):295-325. PubMed ID: 29987748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RAGE signaling in osteoporosis.
    Zhou J; Liu S; Bi S; Kong W; Qian R; Xie X; Zeng M; Jiang X; Liao Z; Shuai M; Liu W; Cheng L; Wu M
    Biomed Pharmacother; 2023 Sep; 165():115044. PubMed ID: 37354815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced Glycation End Products (AGEs), Glutathione and Breast Cancer: Factors, Mechanism and Therapeutic Interventions.
    Sharma AK; Sharma VR; Gupta GK; Ashraf GM; Kamal MA
    Curr Drug Metab; 2019; 20(1):65-71. PubMed ID: 30207227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on signaling for biological- and processed food-related advanced glycation end-products and its role in cancer progression.
    Eva TA; Barua N; Chowdhury MM; Yeasmin S; Rakib A; Islam MR; Emran TB; Simal-Gandara J
    Crit Rev Food Sci Nutr; 2022; 62(10):2655-2672. PubMed ID: 33307763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.